» Articles » PMID: 38893049

Leveraging Cancer Phenotypic Plasticity for Novel Treatment Strategies

Abstract

Cancer cells, like all other organisms, are adept at switching their phenotype to adjust to the changes in their environment. Thus, phenotypic plasticity is a quantitative trait that confers a fitness advantage to the cancer cell by altering its phenotype to suit environmental circumstances. Until recently, new traits, especially in cancer, were thought to arise due to genetic factors; however, it is now amply evident that such traits could also emerge non-genetically due to phenotypic plasticity. Furthermore, phenotypic plasticity of cancer cells contributes to phenotypic heterogeneity in the population, which is a major impediment in treating the disease. Finally, plasticity also impacts the group behavior of cancer cells, since competition and cooperation among multiple clonal groups within the population and the interactions they have with the tumor microenvironment also contribute to the evolution of drug resistance. Thus, understanding the mechanisms that cancer cells exploit to tailor their phenotypes at a systems level can aid the development of novel cancer therapeutics and treatment strategies. Here, we present our perspective on a team medicine-based approach to gain a deeper understanding of the phenomenon to develop new therapeutic strategies.

Citing Articles

Application of an Integrated Single-Cell and Three-Dimensional Spheroid Culture Platform for Investigating Drug Resistance Heterogeneity and Epithelial-Mesenchymal Transition (EMT) in Lung Cancer Subclones.

Chen S, Yu J, Lin Y, Chang Y, Liu N, Chen S Int J Mol Sci. 2025; 26(4).

PMID: 40004228 PMC: 11855057. DOI: 10.3390/ijms26041766.


Modeling Drug Responses and Evolutionary Dynamics Using Patient-Derived Xenografts Reveals Precision Medicine Strategies for Triple-Negative Breast Cancer.

Shea A, Eyal-Lubling Y, Guerrero-Romero D, Manzano Garcia R, Greenwood W, OReilly M Cancer Res. 2024; 85(3):567-584.

PMID: 39514406 PMC: 7617242. DOI: 10.1158/0008-5472.CAN-24-1703.


Advances in Non-Small Cell Lung Cancer: Current Insights and Future Directions.

Garg P, Singhal S, Kulkarni P, Horne D, Malhotra J, Salgia R J Clin Med. 2024; 13(14).

PMID: 39064229 PMC: 11278207. DOI: 10.3390/jcm13144189.

References
1.
Yoshida G, Azuma A, Miura Y, Orimo A . Activated Fibroblast Program Orchestrates Tumor Initiation and Progression; Molecular Mechanisms and the Associated Therapeutic Strategies. Int J Mol Sci. 2019; 20(9). PMC: 6539414. DOI: 10.3390/ijms20092256. View

2.
Su Y, Ko M, Cheng H, Zhu R, Xue M, Wang J . Multi-omic single-cell snapshots reveal multiple independent trajectories to drug tolerance in a melanoma cell line. Nat Commun. 2020; 11(1):2345. PMC: 7214418. DOI: 10.1038/s41467-020-15956-9. View

3.
Mahmoudabadi G, Rajagopalan K, Getzenberg R, Hannenhalli S, Rangarajan G, Kulkarni P . Intrinsically disordered proteins and conformational noise: implications in cancer. Cell Cycle. 2012; 12(1):26-31. PMC: 3570512. DOI: 10.4161/cc.23178. View

4.
. Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018; 392(10159):1736-1788. PMC: 6227606. DOI: 10.1016/S0140-6736(18)32203-7. View

5.
Frayling T . Genome-wide association studies: the good, the bad and the ugly. Clin Med (Lond). 2014; 14(4):428-31. PMC: 4952840. DOI: 10.7861/clinmedicine.14-4-428. View